ArticleIn vivo (Athens, Greece)

High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data.

Mariacarmela Santarpia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.